AVITA Medical, Inc. — Form 8-K Summary
Business context and reporting period
Filed December 3, 2021, under Item 8.01 to clarify the Company’s board meeting and attendance records for the fiscal year ended June 30, 2021. The filing identifies AVITA Medical, Inc. as the registrant and its common stock as trading under the symbol RCEL on Nasdaq.
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The filing does not report operational or financial changes versus a prior period. It only clarifies board meeting activity and attendance.
Management commentary, risks, and unusual items
- The board met nine times during the fiscal year ended June 30, 2021, on dates ranging from August 7, 2020, through January 6, 2021.
- The Chief Executive Officer, who also served as a director, attended eight of the nine meetings.
- The information was furnished under Item 8.01 and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings, except where expressly stated.
- No guidance, outlook, contingencies, risks, or unusual financial items are disclosed.
Important facts for investors to verify
- Confirm the nine board meeting dates and the CEO’s attendance at eight meetings.
- Note the filing’s signature block refers to “Avita Therapeutics, Inc.” while the registrant heading identifies “Avita Medical, Inc.”
- Review the Company’s periodic filings for financial results, liquidity, operating performance, and risk disclosures, which are not included in this 8-K.